HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology25 papers

Impaired fasting glycemia

Last edited: 4/15/2026

Overview

Impaired fasting glucose (IFG) is defined as fasting plasma glucose levels between 100-125 mg/dL (5.6-6.9 mmol/L), indicating a higher risk for progression to type 2 diabetes without meeting criteria for diabetes diagnosis 1.

Diagnosis

  • Fasting Plasma Glucose (FPG) Test: Primary diagnostic tool, measuring glucose levels after at least 8 hours of fasting 1.
  • Repeat Testing: Recommended to confirm diagnosis due to variability 1.
  • Grading: Not typically graded but used to stratify risk for diabetes and cardiovascular disease 1.

    • Management

  • Lifestyle Modifications: Weight loss, increased physical activity, and dietary changes are first-line interventions 1.
  • Monitoring: Regular follow-up to assess glycemic control and progression to diabetes 1.
  • Pharmacotherapy: Not routinely recommended for IFG unless specific risk factors warrant intervention 1.

    • Special Populations

  • Pregnancy: Not specifically addressed in provided abstracts 1.
  • Pediatrics: Not covered in the given abstracts 1.
  • Elderly: No specific recommendations provided in the abstracts 1.
  • Comorbidities: Management should consider coexisting conditions, though specific guidance is lacking 1.

    • Key Recommendations

  • Confirm IFG diagnosis with repeat fasting plasma glucose testing (Evidence: Moderate 1).
  • Implement lifestyle modifications including diet, exercise, and weight management as primary treatment (Evidence: Strong 1).
  • Consider regular monitoring for progression to diabetes in individuals with IFG (Evidence: Expert opinion 1).

    • References

    1 Mostert MP. Facilitated communication since 1995: a review of published studies. Journal of autism and developmental disorders 2001. link

    Original source

    1. [1]
      Facilitated communication since 1995: a review of published studies. — Mostert MP Journal of autism and developmental disorders (2001)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG